Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-34 is a Treg-specific cytokine and mediates transplant tolerance
Séverine Bézie, Elodie Picarda, Jason Ossart, Laurent Tesson, Claire Usal, Karine Renaudin, Ignacio Anegon, Carole Guillonneau
Séverine Bézie, Elodie Picarda, Jason Ossart, Laurent Tesson, Claire Usal, Karine Renaudin, Ignacio Anegon, Carole Guillonneau
View: Text | PDF
Research Article

IL-34 is a Treg-specific cytokine and mediates transplant tolerance

  • Text
  • PDF
Abstract

Cytokines and metabolic pathway–controlling enzymes regulate immune responses and have potential as powerful tools to mediate immune tolerance. Blockade of the interaction between CD40 and CD40L induces long-term cardiac allograft survival in rats through a CD8+CD45RClo Treg potentiation. Here, we have shown that the cytokine IL-34, the immunoregulatory properties of which have not been previously studied in transplantation or T cell biology, is expressed by rodent CD8+CD45RClo Tregs and human FOXP3+CD45RCloCD8+ and CD4+ Tregs. IL-34 was involved in the suppressive function of both CD8+ and CD4+ Tregs and markedly inhibited alloreactive immune responses. Additionally, in a rat cardiac allograft model, IL-34 potently induced transplant tolerance that was associated with a total inhibition of alloantibody production. Treatment of rats with IL-34 promoted allograft tolerance that was mediated by induction of CD8+ and CD4+ Tregs. Moreover, these Tregs were capable of serial tolerance induction through modulation of macrophages that migrate early to the graft. Finally, we demonstrated that human macrophages cultured in the presence of IL-34 greatly expanded CD8+ and CD4+ FOXP3+ Tregs, with a superior suppressive potential of antidonor immune responses compared with non–IL-34–expanded Tregs. In conclusion, we reveal that IL-34 serves as a suppressive Treg–specific cytokine and as a tolerogenic cytokine that efficiently inhibits alloreactive immune responses and mediates transplant tolerance.

Authors

Séverine Bézie, Elodie Picarda, Jason Ossart, Laurent Tesson, Claire Usal, Karine Renaudin, Ignacio Anegon, Carole Guillonneau

×

Figure 1

IL-34 and CD115, but not M-CSF, are involved in CD8+CD45RClo Treg–mediated suppression.

Options: View larger image (or click on image) Download as PowerPoint
IL-34 and CD115, but not M-CSF, are involved in CD8+CD45RClo Treg–mediat...
(A). FACSAria-sorted CD8+CD45RClo Tregs from spleen of naive or 120-day-old AdCD40Ig-treated recipients (n = 6) were analyzed for Il34 mRNA expression by qPCR. Mann-Whitney U test, **P < 0.01. (B) Il34 mRNA expression levels in cardiac grafts from AdCD40Ig-treated recipients on days 5 (n = 3) and 120 (n = 7) after transplantation were compared with those in grafts from nontreated (NT) recipients on days 5 (n = 8), 7 (n = 8) and 120 (n = 6) and with levels in native hearts from naive animals (n = 7). Mann-Whitney U test, *P < 0.05, **P < 0.01, ***P < 0.001. (C–E) The relative proportion of CFSE-labeled LEW.1A dividing CD4+CD25– T cells stimulated with donor LEW.1W pDCs was analyzed after 6 days of culture in the presence of LEW.1A CD8+CD40Ig Tregs at a 1:1 effector/suppressor ratio. Proliferation after the addition of anti–IL-34–blocking Ab (C), anti–M-CSF–blocking Ab (D), or anti-CD115–blocking Ab (E) was evaluated and compared with that of the appropriate isotypic control (n = 4 experiments performed in triplicate). The proportion of dividing CD4+CD25– T cells in the control proliferation condition with pDCs only representing approximately 80% of the cells on day 5 was given a value of 100 in each experiment. Results are expressed as the mean ± SEM of the relative proportion of dividing CD4+CD25– T cells. A representative raw CFSE profile is shown in C (right panel). Kruskal-Wallis and Dunn’s post tests, *P < 0.05 (C–E).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts